Our reports and articles feature research and analysis on topics that matter most in digital health today.
As technology continues to influence healthcare, our insights are designed to help you understand what comes next and make better decisions in digital health.
HealthXL community members and industry leaders from pharma, digital health companies and decentralized trials providers have come together to create this new open-access tool.
The tool helps sponsors select the best digital measurement technologies for clinical trial use in each particular trial.
It also offers vendors a way to prepare a documentation package to support the sponsor evaluation process.
Explore our latest thinking, expert analysis and community insights on what matters most in digital health.
Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.Read more
FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.Read more
Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.Read more